ABflo® 647 Rabbit anti-Goat IgG (Fab) fragment mAb (A22784)
Abclonal ABflo® 647 Rabbit anti-Goat IgG (Fab) fragment mAb (Catalog Number: A22784)
ABflo® 594 Rabbit anti-Goat IgG (Fab) fragment mAb (A22785)
Abclonal ABflo® 594 Rabbit anti-Goat IgG (Fab) fragment mAb (Catalog Number: A22785)
Cell Electroporation upgrade Model EX+
Celetrix PBMC cell electroporation upgrade model EX+ (11-0106) is an upgraded version of model LE+ (11-0101) with larger electroporation volume (600 ul and 1 ml electroporation tubes) and the option of the electrofusion function for...
Cell Electroporation upgrade Model LE+
Celetrix T cell electroporation upgrade model LE+ (11-0101) can be used to transfect a variety of mammalian cell line, especially PBMC, with high-efficiency and low-toxicity electroporation. It can maintain a high level of T cell...
BI-3406
BI-3406 (CAS No.: 2230836-55-0), a highly potent, selective, and orally bioavailable inhibitor of the interaction between KRAS and Son of Sevenless 1 (SOS1) with an IC50 of 6 nM. Synonyms: KRAS and Son of Sevenless 1...
Toralizumab Biosimilar, Anti-human CD40L Antibody | C066P
The cheapest research grade toralizumab biosimilar (anti-human CD40L/CD154 monoclonal antibody, mAb) for ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying...
Satumomab Biosimilar, Anti-human TAG-72 Antibody | C064P
The cheapest research grade satumomab biosimilar (anti-human TAG-72 monoclonal antibody, mAb) for ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying...
Ruplizumab Biosimilar, Anti-human CD40L Antibody | C063P
The cheapest research grade ruplizumab biosimilar (anti-human CD40L/CD40/CD154 monoclonal antibody, mAb) for ELISA, neutralization, in vivo functional assays such as bioanalytical PK and ADA assays, and those in vitro and in vivo assays for studying...
ALTIRATINIB (DCC-2701)
Background Information: Abstract (Ref 1): Altiratinib (DCC-2701) was designed based on the rationale of engineering a single therapeutic agent able to address multiple hallmarks of cancer. Specifically, Altiratinib inhibits not only mechanisms of tumor initiation and...